Trinity Biotech plc (NASDAQ: TRIB) is 139.98% higher on its value in year-to-date trading and has touched a low of $0.56 and a high of $2.83 in the current 52-week trading range. The TRIB stock was last observed hovering at around $2.48 in the recent trading session, with the current loss setting it -0.04% off its average median price target of $4.00 for the next 12 months. It is also 39.0% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 39.0% higher than the price target low of $4.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $2.44, the stock is 3.79% and 32.78% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.2 million and changing -1.61% at the moment leaves the stock 98.73% off its SMA200. TRIB registered 3.33% gain for a year compared to 6-month gain of 138.39%. The firm has a 50-day simple moving average (SMA 50) of $2.0062 and a 200-day simple moving average (SMA200) of $1.3538.
The stock witnessed a 45.03% loss in the last 1 month and extending the period to 3 months gives it a 138.46%, and is -2.75% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.39% over the week and 13.10% over the month.
Trinity Biotech plc (TRIB) has around 579 employees, a market worth around $59.20M and $89.60M in sales. Fwd P/E is 10.33. Profit margin for the company is -34.50%. Distance from 52-week low is 334.94% and -13.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.60%).
Trinity Biotech plc (TRIB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Trinity Biotech plc (TRIB) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Trinity Biotech plc is expected to release its quarterly report on 07/16/2020 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $21.18M over the same period.The EPS is expected to shrink by -28.00% this year, but quarterly earnings will post -18.00% year-over-year. Quarterly sales are estimated to shrink -3.90% in year-over-year returns.
Trinity Biotech plc (TRIB) Top Institutional Holders
32 institutions hold shares in Trinity Biotech plc (TRIB), with 3.81M shares held by insiders accounting for 18.25% while institutional investors hold 54.31% of the company’s shares. The shares outstanding are 20.90M, and float is at 18.99M with Short Float at 3.48%. Institutions hold 44.40% of the Float.
Trinity Biotech plc (TRIB): Who are the competitors?
The company’s main competitors (and peers) include Chembio Diagnostics Inc. (CEMI) that is trading -18.71% down over the past 12 months. Abbott Laboratories (ABT) is 10.93% up on the 1-year trading charts. Short interest in the company’s stock has risen 7.45% from the last report on May 28, 2020 to stand at a total of 0.61 million short shares sold with a short interest ratio of 0.57.